This analysis revealed that some individuals with a pathogenic variant in PALB2 were diagnosed with breast cancer well before the age of 50 (Supplemental Table 5) and had a similar risk to those with a BRCA2 variant before the age of 50 (Figure 2A) when, until recently, guidelines recommended beginning screening for everyone. This evidence concerns the gene BRCA2 and breast carcinoma.